Minerva Neurosciences, Inc.: 10-Q filed 2022-11-09

Name: Minerva Neurosciences, Inc.: 10-Q filed 2022-11-09
Creator: Minerva Neurosciences, Inc.

What Minerva Neurosciences, Inc. reported in its quarterly report filed 2022-11-09 (fiscal Q3 2022): 25 published measures, 79 facts as tagged in accession 0000950170-22-023496.

This filing

Form: 10-Q (quarterly report)
Filed: 2022-11-09
Fiscal period: fiscal Q3 2022
Accession: 0000950170-22-023496 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Minerva Neurosciences, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2022-09-30	59,759,109	USD
At 2021-12-31	77,121,918	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2022-09-30	74,004,955	USD
At 2021-12-31	69,146,275	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2022-09-30	-14,245,846	USD
At 2022-06-30	-8,382,244	USD
At 2022-03-31	-736,130	USD
At 2021-12-31	7,975,643	USD
At 2021-09-30	28,077,948	USD
At 2021-06-30	36,168,829	USD
At 2021-03-31	45,373,932	USD
At 2020-12-31	52,662,601	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2022-09-30	40,220,008	USD
At 2021-12-31	60,755,080	USD
At 2021-09-30	65,588,119	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-6,900,476	USD	92
2022-01-01 to 2022-09-30	-25,382,619	USD	273
2022-04-01 to 2022-06-30	-8,717,714	USD	91
2022-01-01 to 2022-03-31	-9,764,429	USD	90
2021-07-01 to 2021-09-30	-9,205,407	USD	92
2021-01-01 to 2021-09-30	-28,599,303	USD	273
2021-04-01 to 2021-06-30	-10,589,163	USD	91
2021-01-01 to 2021-03-31	-8,804,733	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	-20,535,067	USD	273
2021-01-01 to 2021-09-30	-19,768,833	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	-5	USD	273
2021-01-01 to 2021-09-30	60,000,000	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2022-09-30	-360,084,018	USD
At 2021-12-31	-334,701,399	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	5,340,193	shares	92
2022-01-01 to 2022-09-30	5,340,195	shares	273
2021-07-01 to 2021-09-30	5,340,196	shares	92
2021-01-01 to 2021-09-30	5,340,196	shares	273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	5,340,193	shares	92
2022-01-01 to 2022-09-30	5,340,195	shares	273
2021-07-01 to 2021-09-30	5,340,196	shares	92
2021-01-01 to 2021-09-30	5,340,196	shares	273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-1.29	USD/shares	92
2022-01-01 to 2022-09-30	-4.75	USD/shares	273
2021-07-01 to 2021-09-30	-1.72	USD/shares	92
2021-01-01 to 2021-09-30	-5.36	USD/shares	273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-1.29	USD/shares	92
2022-01-01 to 2022-09-30	-4.75	USD/shares	273
2021-07-01 to 2021-09-30	-1.72	USD/shares	92
2021-01-01 to 2021-09-30	-5.36	USD/shares	273

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	3,161,135	USD	273
2021-01-01 to 2021-09-30	4,014,650	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	-5,207,148	USD	92
2022-01-01 to 2022-09-30	-20,161,595	USD	273
2021-07-01 to 2021-09-30	-7,517,618	USD	92
2021-01-01 to 2021-09-30	-23,988,432	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2022-09-30	44,840,758	USD
At 2021-12-31	62,201,439	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2022-09-30	2,196,859	USD
At 2021-12-31	2,818,954	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2022-09-30	532,888	USD
At 2021-12-31	1,853,215	USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

Period	Value	Unit	Days
At 2022-09-30	14,869,399	USD
At 2021-12-31	14,869,399	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	5,207,148	USD	92
2022-01-01 to 2022-09-30	20,161,595	USD	273
2021-07-01 to 2021-09-30	7,517,618	USD	92
2021-01-01 to 2021-09-30	23,988,432	USD	273

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	2,367,364	USD	92
2022-01-01 to 2022-09-30	11,459,205	USD	273
2021-07-01 to 2021-09-30	4,512,853	USD	92
2021-01-01 to 2021-09-30	13,292,488	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2022-09-30	5,340,193	shares
At 2021-12-31	5,340,196	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit	Days
At 2022-09-30	40,320,008	USD
At 2021-09-30	65,688,119	USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	-25,382,619	USD	273
2021-01-01 to 2021-09-30	-28,599,303	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2022-07-01 to 2022-09-30	2,839,784	USD	92
2022-01-01 to 2022-09-30	8,702,390	USD	273
2021-07-01 to 2021-09-30	3,004,765	USD	92
2021-01-01 to 2021-09-30	10,695,944	USD	273

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2022-01-01 to 2022-09-30	-1,320,327	USD	273
2021-01-01 to 2021-09-30	204,895	USD	273

Inspect the source

Entity: Minerva Neurosciences, Inc. / CIK 0001598646
Captured: 2026-09-20 09:25 UTC
SEC response SHA-256: 7b57da641574943cc8f7ca81f9c94ea1ff7a872915407c01165fb2137ec7efc4

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001598646.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))